about
Altered intracellular localization and mobility of SBDS protein upon mutation in Shwachman-Diamond syndromeEndosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy.Varied sensitivity to therapy of HIV-1 strains in CD4+ lymphocyte sub-populations upon ART initiation.Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytesLack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets.Establishment and molecular mechanisms of HIV-1 latency in T cells.Latency profiles of full length HIV-1 molecular clone variants with a subtype specific promoter.Altered dynamics and differential infection profiles of lymphoid and myeloid cell subsets during acute and chronic HIV-1 infection.Interplay between viral Tat protein and c-Jun transcription factor in controlling LTR promoter activity in different human immunodeficiency virus type I subtypes.Quantitation of HIV-1 DNA with a sensitive TaqMan assay that has broad subtype specificity.Dendritic cell type-specific HIV-1 activation in effector T cells: implications for latent HIV-1 reservoir establishment.An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infectionHuman immunodeficiency virus type 1 gp120 envelope characteristics associated with disease progression differ in family members infected with genetically similar viruses.Differential proviral latency of the HIV-1 subtypes B and AE.Myeloid Dendritic Cells Induce HIV Latency in Proliferating CD4 T CellsProgrammed cell death-1 contributes to the establishment and maintenance of HIV-1 latencyCD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular CytotoxicityDendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathwayDiverse effects of interferon alpha on the establishment and reversal of HIV latencyModulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of In Vitro versus In Vivo ModelsCombination Immune Checkpoint Blockade to Reverse HIV Latency
P50
Q21135349-04FFEB37-7644-4BF6-A6C7-267C12F29400Q33899570-B0F3A85A-4F11-49F3-B6BF-C2689C6933F2Q34418967-446FFD04-58E1-4BDD-9177-B2309A28B3D0Q34649701-65747A67-F536-4792-8CE3-A3644CAAA0F3Q37366730-943C277A-3704-430F-87B9-D7102358F61DQ38129514-DFD6FD20-9378-4141-B4F3-234B4CF4C137Q38591360-6A67124A-C2F0-4BB0-A22C-414236D802ACQ38935949-7EC5D0EE-53A7-41AC-9203-C264FBDD15EFQ39032300-794656A2-04B3-45BB-B3E5-62F5FD857B4EQ39261045-813B5B06-A720-49DB-B113-54A8D52EB1C9Q41433047-67A9BCE2-CEC3-4E15-9CBE-C9D08BF05EAAQ41961224-2E2BE729-7DC2-4F5E-8B7F-BCDB1F283F48Q45354589-33CC0E3D-EA17-41A7-B352-91E0C440CADEQ45743805-3FC0FCC9-7A85-4D2E-9F33-C7B4F21A43B4Q58003754-8BF8CD38-0094-445A-ABCF-C34BA9730885Q58003757-7C3A8989-B608-4CD3-96AC-879A36F4C024Q63408824-9F6F28D4-19BA-41A4-BE03-86F98106AED2Q64099960-DF316D8D-7254-4A3F-9406-60645369A272Q89935915-1045118F-E9C8-40B8-AA94-B600692E48E3Q92340123-8E8FBB4C-2346-404C-9380-5F0726CB93E9Q92977244-570066A2-090D-4AB8-BC77-EFD2605DB33C
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Renee M van der Sluis
@ast
Renee M van der Sluis
@en
Renee M van der Sluis
@es
Renee M van der Sluis
@nl
Renee M van der Sluis
@sl
type
label
Renee M van der Sluis
@ast
Renee M van der Sluis
@en
Renee M van der Sluis
@es
Renee M van der Sluis
@nl
Renee M van der Sluis
@sl
prefLabel
Renee M van der Sluis
@ast
Renee M van der Sluis
@en
Renee M van der Sluis
@es
Renee M van der Sluis
@nl
Renee M van der Sluis
@sl
P1006
P214
P1006
P106
P21
P214
P31
P496
0000-0002-7668-2517
P7859
viaf-305820685